-- Xuanzhu Biopharmaceutical (HKG:2575) said the Hong Kong Stock Exchange has granted listing approval for its Hong Kong share full circulation application, according to a Friday bourse filing.
The approval covers the conversion of about 357.2 million unlisted shares into Hong Kong-listed shares.
The converted shares represent about 69% of the company's total share capital.